The next ESIL pitch session will be held online on June 25th, from 5 to 6 PM CEST.
Eight companies from the Ehealth/Medtech sector will be presented. All these Series A deeptech companies are part of the European Invest Horizon 2020 acceleration program, and are looking for funds to continue their growth.
3D Imaging Software for Bone Diagnosis
A medical imaging software development company in four key medical fields: arrhythmias, aneurysm, epilepsy and osteoporosis. They offer the medical technology industry fast and low-cost pathways for the creation of innovative and advanced solutions. They also provide an effective means of bringing these solutions to a growing global market. They achieve this by means of an in-house software development platform for the rapid prototyping of medical imaging applications.
Sales launch in 2018: 6 unites/ € 60K, pipeline > € 300K, CE Mark | € 1.8 M sought
Treatment of Localized Adiposity
The company has developed a technology that radically eliminates localized body fat excess (adiposity) and provides results never achieved until now: up to 5 cm. waistline reduction after one 20-minutes session. The company has developed a non-invasive medical device that also uses digital management of ultrasound, shape recognition based on based on IA, augmented reality guidance of the physician. This medical device is being CE marked and should reach the market this year.
The CE marking is in process (electrical tests validated, and technical file being audited). It will be followed by a short test phase in Paris before the beginning of the distribution | 5 M€ sought
Digital Health – Data Brooker
The company collects and processes pharmacies commercial data to build up a panel. It’s a data broker as SAAS provider for pharmacies, pharmacy chains, pharmaceutical labs. The data is accessed for their customers through APIs & self-service apps. They only collect commercial data, excluding any « personal » data. Data are extracted hourly from the pharmacy ERP and are only extracted through an explicit agreement and contract with the pharmacy owner. In these General Conditions, the pharmacy owner concedes the right to collect, process and commercialize the data.
They have already deployed the solution on 5,000 point of sales with a steady growth of the panel. | €2.5 M sought
Biotech – Neurodegenerative
A biopharmaceutical company dedicated to developing first in class molecules that address important medical needs in the field of neurodegenerative diseases and in the area of deafness.
All data generated from in vitro test methods enable to demonstrate the positive impact of the company on: Induction of neuronal differentiation of murine and human progenitor cells; Protection against toxicity-induced by glutamate and oxidative stress; Stimulation of connections between spiral neuronal ganglion cells and ciliated cells, which are responsible for hearing
Efficacity results from in vivo test methods support that they represent a new class of molecules effective for the purpose of treating patients with neuropathy/synaptopathy linked to hearing loss. | €8 M sought
Medical Device – Surgical Instrument for Gynecology
The company aims at serving the gynecology market with a new generation of pain-free single use surgical instrument, to replace the current middle-age painful cervical forceps affecting more than 75 million women every year in routine interventions requiring access to the uterine cavity. The company innovates women's care with new surgical instrument for gentler and more modern gynecological procedures.
12 reference letters from Medical Doctors | €3.5 M sought
Medical Device - Virtual Reality Solution
A company specialized in innovative medical devices. They offer healthcare facilities a therapeutic virtual reality solution aimed to alleviate the pain and anxiety of their hospitalized patients. Thanks to a virtual reality headset and a headphone, a patient is transported according to his preferences in rich and lively natural 3D environments like a forest or a mountain. Developed in collaboration with doctors, their virtual experiments are optimized for relaxation and pain distraction through advanced psychological principles such as hypnosis, music therapy or cardiac coherence induction.
They will reach > € 1M orders in 2019 | €2.5 M sought
Neurosurgical Platform - Glioblastoma
The company is developing a neurosurgical platform, built around a microrobot to deliver drugs in the brain for targeted therapies. The company as a first application is targeting glioblastoma, a deadly malignant and infiltrative brain cancer with limited survival time (12-16 months).
The technology is currently developed and tested inside hydrogel-based brain models and will be tested on preclinical tests starting in 2020 | €3.5 M sought
The company seeks, develops and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases. The purpose of the company is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice. Their know-how is based on the detection of blood biomarkers.
Currently their biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of the Alzheimer’s disease | €2.5 M sought